Literature DB >> 11510298

Loss of phospholipids asymmetry in red blood cells contributes to anemia in uremic patients.

Q Y Kong1, X Wu, J Li, W X Peng, R Ye, B Lindholm, T Wang.   

Abstract

Anemia is common in dialysis patients. Change in phospholipids asymmetry in red blood cells (RBCs) may affect the removal of RBCs from the circulation and thus shorten the lifespan of RBCs. In the present study, we investigated phospholipids asymmetry in RBCs in uremic patients and its relationship with anemia. We studied 34 continuous ambulatory peritoneal dialysis (CAPD) patients (age: 51 +/- 15 years), 73 hemodialysis (HD) patients (age: 48 +/- 12 years), 8 pre-dialysis renal-failure patients (age: 42 +/- 21 years), and 16 healthy controls (age: 32 +/- 9 years). All patients were clinically stable. Phospholipids asymmetry as measured by phosphatidylserine exposure was determined by a flow-cytometric annexin V-binding assay. Hemoglobin levels were 93 +/- 20 g/L, 83 +/- 17 g/L, 78 +/- 21 g/L, and 145.8 +/- 12.5 g/L for CAPD patients, pre-dialysis patients, HD patients, and healthy controls respectively. Phosphatidylserine exposure in RBCs was significantly higher in uremic patients as compared with healthy controls, especially in HD patients--whose values were significantly higher than values seen in CAPD patients and pre-dialysis patients. No significant difference was seen in RBC phosphatidylserine exposure between pre-dialysis patients and CAPD patients. Cells positive for annexin V binding were 1.58%, 1.40%, 2.11%, and 0.71% for CAPD patients, pre-dialysis patients, HD patients, and healthy controls respectively. Significant reverse correlations were seen between annexin V and hemoglobin (r = -0.381, p < 0.001), and between annexin V and hematocrit (r = -0.355, p < 0.001). Our results suggest that (1) anemia is common in our uremic patients, especially in HD patients; and (2) anemia in uremic patients may be partly related to the loss of phospholipids asymmetry in RBCs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510298

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  4 in total

1.  Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.

Authors:  Amit A Joharapurkar; Vishal J Patel; Samadhan G Kshirsagar; Maulik S Patel; Hardikkumar H Savsani; Chetan Kajavadara; Darshan Valani; Mukul R Jain
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-04-30

2.  Upregulation of EHD2 after intracerebral hemorrhage in adult rats.

Authors:  Kaifu Ke; Ying Rui; Lei Li; Heyi Zheng; Wei Xu; Xiang Tan; Jianhua Cao; Xiaoyan Wu; Gang Cui; Maohong Cao
Journal:  J Mol Neurosci       Date:  2014-03-25       Impact factor: 3.444

Review 3.  Pros and cons of phospholipid asymmetry in erythrocytes.

Authors:  Aiswarya Sathi; Vidya Viswanad; T P Aneesh; B Anil Kumar
Journal:  J Pharm Bioallied Sci       Date:  2014-04

4.  Erythrophagocytosis of lead-exposed erythrocytes by renal tubular cells: possible role in lead-induced nephrotoxicity.

Authors:  So-Youn Kwon; Ok-Nam Bae; Ji-Yoon Noh; Keunyoung Kim; Seojin Kang; Young-Jun Shin; Kyung-Min Lim; Jin-Ho Chung
Journal:  Environ Health Perspect       Date:  2014-10-10       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.